acetylcarnitine has been researched along with Chronic Disease in 12 studies
Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A panel of gut-related biomarkers including metabolites of the choline/carnitine- pathway (acetyl-L-carnitine, betaine, choline, γ-butyrobetaine, L-carnitine and trimethylamine-N-oxide [TMAO]) and the gut peptide, Trefoil factor-3 (TFF-3), were investigated in 1,783 patients with worsening HF enrolled in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort and associations with HF severity and outcomes, and use in risk stratification were assessed." | 4.12 | Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium. ( Anker, SD; Cleland, JG; Israr, MZ; Lang, CC; Metra, M; Ng, LL; Salzano, A; Samani, NJ; Suzuki, T; van Veldhuisen, DJ; Voors, AA; Zannad, F; Zhan, H, 2022) |
| "The effects of chronic hypoxia on cardiac membrane fatty acids and on lipid peroxidation were examined, as well as the effect of l-carnitine (LCAR), which suppresses lipid peroxidation, on this process." | 3.74 | Change in the membranous lipid composition accelerates lipid peroxidation in young rat hearts subjected to 2 weeks of hypoxia followed by hyperoxia. ( Hamaoka, K; Itoi, T; Nakanishi, H; Oka, T; Taguchi, R; Terada, N, 2008) |
| " dosage of 1." | 2.67 | Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct. ( Cicerano, U; De Chiara, S; Gallotta, G; Mansi, L; Postiglione, A; Salvatore, M; Schettini, G; Soricelli, A, 1991) |
| "L-acetylcarnitine treatment enhanced mGlu2/3 receptor protein levels in the dorsal region of the spinal cord." | 1.46 | Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. ( Battaglia, G; Bernabucci, M; Bruno, V; Cannella, M; Gradini, R; Imbriglio, T; Mascio, G; Nicoletti, F; Notartomaso, S; Scarselli, P; Zappulla, C, 2017) |
| ") at a dosage of 1." | 1.28 | Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine. ( Cicerano, U; De Chiara, S; Gallotta, G; Mancini, M; Postiglione, A; Salvatore, M; Soricelli, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Israr, MZ | 1 |
| Zhan, H | 1 |
| Salzano, A | 1 |
| Voors, AA | 1 |
| Cleland, JG | 1 |
| Anker, SD | 1 |
| Metra, M | 1 |
| van Veldhuisen, DJ | 1 |
| Lang, CC | 1 |
| Zannad, F | 1 |
| Samani, NJ | 1 |
| Ng, LL | 1 |
| Suzuki, T | 1 |
| Skoromets, AA | 1 |
| Kotov, SV | 1 |
| Voronkov, PB | 1 |
| Popova, VV | 1 |
| Zubkova, TG | 1 |
| Kiselev, AV | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Notartomaso, S | 1 |
| Mascio, G | 1 |
| Bernabucci, M | 1 |
| Zappulla, C | 1 |
| Scarselli, P | 1 |
| Cannella, M | 1 |
| Imbriglio, T | 1 |
| Gradini, R | 1 |
| Battaglia, G | 2 |
| Bruno, V | 1 |
| Nicoletti, F | 2 |
| Oka, T | 1 |
| Itoi, T | 1 |
| Terada, N | 1 |
| Nakanishi, H | 1 |
| Taguchi, R | 1 |
| Hamaoka, K | 1 |
| Chiechio, S | 1 |
| Copani, A | 1 |
| Zammataro, M | 1 |
| Gereau, RW | 1 |
| Kotil, K | 1 |
| Kirali, M | 1 |
| Eras, M | 1 |
| Bilge, T | 1 |
| Uzun, H | 1 |
| Bidzinska, B | 2 |
| Petraglia, F | 2 |
| Angioni, S | 2 |
| Genazzani, AD | 2 |
| Criscuolo, M | 2 |
| Ficarra, G | 2 |
| Gallinelli, A | 2 |
| Trentini, GP | 2 |
| Genazzani, AR | 2 |
| Michalak, A | 1 |
| Qureshi, IA | 1 |
| Biagiotti, G | 1 |
| Cavallini, G | 1 |
| Postiglione, A | 2 |
| Soricelli, A | 2 |
| Cicerano, U | 2 |
| Mansi, L | 1 |
| De Chiara, S | 2 |
| Gallotta, G | 2 |
| Schettini, G | 1 |
| Salvatore, M | 2 |
| Mancini, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.[NCT02141035] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for acetylcarnitine and Chronic Disease
| Article | Year |
|---|---|
Topics: Acetylcarnitine; Aged; Cardiovascular Diseases; Carnitine; Cerebrovascular Disorders; Chronic Diseas | 2021 |
Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report.
Topics: Acetylcarnitine; Acute Disease; Administration, Oral; Adult; Aged; Chronic Disease; Humans; Male; Mi | 2001 |
Effect of acute administration of L-acetyl carnitine on cerebral blood flow in patients with chronic cerebral infarct.
Topics: Acetylcarnitine; Aged; Cerebral Infarction; Cerebrovascular Circulation; Cerebrovascular Disorders; | 1991 |
9 other studies available for acetylcarnitine and Chronic Disease
| Article | Year |
|---|---|
Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium.
Topics: Acetylcarnitine; Biomarkers; Carnitine; Choline; Chronic Disease; Heart Failure; Humans | 2022 |
Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain.
Topics: Acetylcarnitine; Amitriptyline; Analgesics; Animals; Chronic Disease; Disease Models, Animal; Epigen | 2017 |
Change in the membranous lipid composition accelerates lipid peroxidation in young rat hearts subjected to 2 weeks of hypoxia followed by hyperoxia.
Topics: Acetylcarnitine; Age Factors; Animals; Antioxidants; Carnitine; Catalase; Cell Membrane; Chronic Dis | 2008 |
Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain.
Topics: Acetylcarnitine; Animals; Chronic Disease; Epigenesis, Genetic; Humans; Pain; Pain Management; Recep | 2010 |
Neuroprotective effects of acetyl-L-carnithine in experimental chronic compression neuropathy. A prospective, randomized and placebo-control trials.
Topics: Acetylcarnitine; Animals; Axons; Chronic Disease; Decompression, Surgical; Disease Models, Animal; F | 2007 |
Effect of different chronic intermittent stressors and acetyl-l-carnitine on hypothalamic beta-endorphin and GnRH and on plasma testosterone levels in male rats.
Topics: Acetylcarnitine; Animals; beta-Endorphin; Chronic Disease; Ether; Gonadotropin-Releasing Hormone; Hy | 1993 |
Acetyl-L-carnitine effect on pituitary and plasma beta-endorphin responsiveness to different chronic intermittent stressors.
Topics: Acetylcarnitine; Animals; beta-Endorphin; Chronic Disease; Cold Temperature; Ether; Male; Pituitary | 1993 |
Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine.
Topics: Acetylcarnitine; Acyl Coenzyme A; Ammonia; Animals; Benzoates; Benzoic Acid; Carnitine; Chronic Dise | 1995 |
Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine.
Topics: Acetylcarnitine; Aged; Arteriosclerosis; Carnitine; Cerebrovascular Circulation; Cerebrovascular Dis | 1990 |